Cost-effectiveness of selective internal radiation therapy with Y-90 resin microspheres for intermediate- and advanced-stage hepatocellular carcinoma in Brazil

References

• Crissien AM, Frenette C. Current management of hepatocellular carcinoma. Gastroenterol Hepatol (NY). 2014;10(3):153–161.
   PubMedGoogle Scholar
• Kumar M, Panda D. Role of supportive care for terminal stage hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4(Suppl 3): s 130–9.
   Google Scholar
• Sun VC-Y, Sarna L. Symptom management in hepatocellular carcinoma. Clin J Oncol Nurs. 2008;12(5):759–766.
   PubMed Web of Science ®Google Scholar
• Rich NE, Yopp AC, Singal AG. Medical management of hepatocellular carcinoma. J Oncol Pract. 2017;13(6):356–364.
   PubMed Web of Science ®Google Scholar
• Dimitroulis D, Damaskos C, Valsami S, et al. From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol. 2017;23(29):5282–5294.
   PubMed Web of Science ®Google Scholar
• Fan S, Eiser C, Ho M. Health-Related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroenterol Hepatol. 2010;8(7):559–564.e10.
   PubMed Web of Science ®Google Scholar
• Zabora J, BrintzenhofeSzoc K, Curbow B, et al. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10(1):19–28.
   PubMed Web of Science ®Google Scholar
• Kohn CG, Singh P, Korytowsky B, et al. Humanistic and economic burden of hepatocellular carcinoma: systematic literature review. Am J Manag Care. 2019;25(2):SP61–SP73.
   PubMedGoogle Scholar
• Shih W-MJ, Hsiao P-J, Chen M-L, et al. Experiences of family of patient with newly diagnosed advanced terminal stage hepatocellular cancer. Asian Pac J Cancer Prev. 2013;14(8):4655–4660.
   PubMedGoogle Scholar
• Gondek K, Lang K, Danchenko N, et al. Economic costs of hepatocellular carcinoma in the United States. J Clin Oncol. 2008;26(15_suppl):6555–6555.
   Google Scholar
• Scalone L, Fagiuoli S, Ciampichini R, et al. The societal burden of chronic liver diseases: results from the COME study. BMJ Open Gastroenterol. 2015;2(1):e000025–e000025.
   Google Scholar
• European Association for the Study of the Liver. Electronic address: [email protected]; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• The Global Cancer Observatory (International Agency for Research on Cancer - World Health Organization). Brazil fact sheet [Internet]. 2021. [cited 2021 Jun 24]. Available from: https://gco.iarc.fr/today/data/factsheets/populations/76-brazil-fact-sheets.pdf.
   Google Scholar
• Fernandes GDS, Campos D, Ballalai A, et al. Epidemiological and clinical patterns of newly diagnosed hepatocellular carcinoma in Brazil: the need for liver disease screening programs based on real-world data. J Gastrointest Cancer. 2021;52(3):952–958.
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma. ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;29(Suppl 4):iv238–iv255.
   Google Scholar
• Chagas AL, Mattos AA, de Carrilho FJ, et al. Brazilian society of hepatology updated recommendations for diagnosis and treatment of hepatocellular carcinoma. Arq Gastroenterol. 2020;57(suppl 1):1–20.
   PubMedGoogle Scholar
• Sociedade Brasileira de Oncologia Clínica. Carcinoma hepatocelular. Diretrizes 2021 - Actualização. 2021; [cited 2021 Jul 8]. Available from: https://www.scielo.br/j/ag/a/jnWVcf9QdnNQNgsYQ8KxjBk/
   Google Scholar
• Díaz LA, Barrera MF. Clasificación Barcelona Clinic Liver Cancer (BCLC) de carcinoma hepatocelular. Gastroenterol latinoam. 2015;6(1):63–68.
   Google Scholar
• Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–338.
   PubMed Web of Science ®Google Scholar
• Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2011;(3):CD004787.
   PubMedGoogle Scholar
• Forner A, Llovet JM, Bruix J. Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol. 2012;56(4):984–986.
   PubMed Web of Science ®Google Scholar
• Ahmed S, de Souza NN, Qiao W, et al. Quality of life in hepatocellular carcinoma patients treated with transarterial chemoembolization. HPB Surg. 2016;2016;2016:6120143.
   PubMedGoogle Scholar
• Hinrichs JB, Hasdemir DB, Nordlohne M, et al. Health-related quality of life in patients with hepatocellular carcinoma treated with initial transarterial chemoembolization. Cardiovasc Intervent Radiol. 2017;40(10):1559–1566.
   PubMed Web of Science ®Google Scholar
• Steel JL, Eton DT, Cella D, et al. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol. 2006;17(2):304–312.
   PubMed Web of Science ®Google Scholar
• Pitton MB, Kloeckner R, Ruckes C, et al. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2015;38(2):352–360. Apr
   PubMed Web of Science ®Google Scholar
• Megías Vericat JE, García Marcos R, López Briz E, et al. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: a study of effectiveness, safety and costs. Radiologia. 2015;57(6):496–504.
   PubMedGoogle Scholar
• Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30(1):6–25.
   PubMed Web of Science ®Google Scholar
• Kolligs FT, Bilbao JI, Jakobs T, et al. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. 2015;35(6):1715–1721.
   PubMed Web of Science ®Google Scholar
• Fateen W, Khan F, O'Neill RJ, et al. Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Hepatocell Carcinoma. 2017;4:123–130.
   PubMed Web of Science ®Google Scholar
• Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–1636.
   PubMed Web of Science ®Google Scholar
• Gill J, Baiceanu A, Clark PJ, et al. Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey. Future Oncol. 2018;14(17):1701–1710.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
   PubMed Web of Science ®Google Scholar
• Brunocilla PR, Brunello F, Carucci P, et al. Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol. 2013;30(1):345.
   PubMed Web of Science ®Google Scholar
• Cabrera R. Multicenter, randomized pilot study of the effect of sorafenib dosing schedule on tolerability and drug delivery. Hepatology. 2017;66(SI):731A–7732A.
   Google Scholar
• Brose MS, Frenette CT, Keefe SM, et al. Management of sorafenib-related adverse events: a clinician’s perspective. Semin Oncol. 2014;41(Suppl 2):S1–S16.
   PubMedGoogle Scholar
• Pereira H, Bouattour M, Dioguardi Burgio M, et al. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial). Eur J Cancer. 2021;154:46–56.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020 May 13;382(20):1894–1905.
   PubMed Web of Science ®Google Scholar
• de Castro T, Jochheim LS, Bathon M, et al. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol. 2022;14:17588359221080298.
   Web of Science ®Google Scholar
• D’Alessio A, Fulgenzi CAM, Nishida N, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh a and B cirrhosis: a real-world study. Hepatology. 2022;76(4):1000–1012.
   PubMed Web of Science ®Google Scholar
• Lo SH, Sharma R, Costentin CE, et al. Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study. Future Oncol. 2021;17(32):4275–4287.
   PubMed Web of Science ®Google Scholar
• Miller JC, Blaszkowsky LS, Kalva SP. Selective internal radiation therapy—tackling the tumor, sparing the organ. US Oncol Rev. 2008;4(1):68–71. Available from: https://touchoncology.com/wp-content/uploads/sites/2/2015/07/private_articles_18385_pdf_kalva.pdf
   Google Scholar
• Sundram FX, Buscombe JR. Selective internal radiation therapy for liver tumours. Clin Med (Lond). 2017;17(5):449–453
   PubMed Web of Science ®Google Scholar
• Chow PKH, Gandhi M, Tan S-B, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–1921. Jul
   PubMed Web of Science ®Google Scholar
• Helmberger T, Golfieri R, Pech M, et al. Clinical application of trans-arterial radioembolization in hepatic malignancies in Europe: first results from the prospective multicentre observational study CIRSE Registry for SIR-Spheres Therapy (CIRT). Cardiovasc Intervent Radiol. 2021;44(1):21–35.
   PubMed Web of Science ®Google Scholar
• Loffroy R, Ronot M, Greget M, et al. Short-term safety and quality of life outcomes following radioembolization in primary and secondary liver tumours: a multi-Centre analysis of 200 patients in France. Cardiovasc Intervent Radiol. 2021;44(1):36–49.
   PubMed Web of Science ®Google Scholar
• Frantz S, Matsuoka L, Vaheesan K, et al. Multicenter evaluation of survival and toxicities of hepatocellular carcinoma following radioembolization: analysis of the RESiN registry. J Vasc Interv Radiol. 2021;32(6):845–852.
   PubMed Web of Science ®Google Scholar
• Gramenzi A, Golfieri R, Mosconi C, et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 2015;35(3):1036–1047.
   PubMed Web of Science ®Google Scholar
• de la Torre MA, Buades-Mateu J, de la Rosa PA, et al. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. Liver Int. 2016;36(8):1206–1212.
   PubMed Web of Science ®Google Scholar
• Shaya FT, Breunig IM, Seal B, et al. Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare. Pharmacoeconomics. 2014;32(1):63–74. Jan
   PubMed Web of Science ®Google Scholar
• Edeline J, Crouzet L, Campillo-Gimenez B, et al. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging. 2016;43(4):635–643.
   PubMed Web of Science ®Google Scholar
• Gaia S, Tabone M, Cantamessa A, et al. 257 Sorafenib versus radioembolization with y90: clinical evaluation and survival in patients with advanced hepatocellular carcinoma and cirrhosis. J Hepatol. 2013;58:S109–S110.
   Web of Science ®Google Scholar
• Cantamessa A, Gaia S, Tabone M, et al. Sorafenib versus Y90-Radioembolization: a preliminary assessment of tolerability and survival in advanced Mono-lobar hepatocellular carcinoma. Dig Liver Dis. 2014;46:e64. Available from:
   Google Scholar
• Martelletti C, Gesualdo M, Carucci P, et al. The Piedmont-Aosta valley oncology network experience in locally advanced HCC with intrahepatic neoplastic portal vein thrombosis: y 90-radioembolization versus sorafenib. Dig Liver Dis. 2020;52:e53.
   Google Scholar
• Palmer DH, Hawkins NS, Vilgrain V, et al. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. Future Oncol. 2020;16(1):4315–4325.
   PubMed Web of Science ®Google Scholar
• Agência Nacional de Saúde Suplementar. Rol de procedimentos e eventos em saúde. Anexo II. Diretrizes de utilização para cobertura de procedimentos na saúde suplementar. RN 465/2021 e suas alterações [Internet]. [cited 2023 Jan 17]. Available from: https://www.gov.br/ans/pt-br/arquivos/assuntos/consumidor/o-que-seu-plano-deve-cobrir/Anexo_II_DUT_2021_RN_465.2021_tea.br_RN473_RN477_RN478_RN480_RN513_RN536_RN537_RN538_RN539_RN540_RN541_RN542.pdf.
   Google Scholar
• Ministério da Saúde (Brasil). Diretrizes metodológicas: diretriz de avaliação econômica. Brasília: Ministério da Saúde; 2014.
   Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices--overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Heal [Internet]. 2012;15(6):796–803. Available from:
   PubMed Web of Science ®Google Scholar
• Sirtex. Questionnaire for clinician validation in Brazil. Data on file. 2021.
   Google Scholar
• Walton M, Wade R, Claxton L, et al. Selective internal radiation therapies (SIRT) for treating hepatocellular carcinoma [ID1276]. Assessment Report [Internet]. 2019. Available from: https://www.nice.org.uk/guidance/ta688/documents/assessment-report.
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York (NY): Oxford University Press; 2006.
   Google Scholar
• National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal [Internet]. London; 2013. [cited 2021 May 14]. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.
   Google Scholar
• Scottish Medicine Consortium. 2nd Re-submission: sorafenib 200mg film-coated tablets (Nexavar®) SMC No. (482/08) [Internet]. 2015. [cited 2021 Apr 9]. p. 1–12. Available from: https://www.scottishmedicines.org.uk/media/2325/sorafenib_nexavar_2nd_resubmission_final_dec_2015_for_website.pdf.
   Google Scholar
• National Institute for Health and Care Excellence. Sorafenib for treating advanced hepatocellular carcinoma. Technology appraisal guidance [TA474] [Internet]. 2017. [cited 2021 Apr 9]. Available from: https://www.nice.org.uk/guidance/ta474.
   Google Scholar
• National Institute for Health and Care Excellence. Lenvatinib for untreated advanced hepatocellular carcinoma. Technology appraisal guidance [TA551] [Internet]. 2018 [cited 2021 Apr 9]. Available from: https://www.nice.org.uk/guidance/ta551.
   Google Scholar
• National Institute for Health and Care Excellence. Regorafenib for previously treated hepatocellular carcinoma [ID1519] (rapid review TA514) [Internet]. 2018. [cited 2021 Apr 9]. Available from: https://www.nice.org.uk/guidance/ta555/documents/committee-papers.
   Google Scholar
• Muszbek N, Remak E, Evans R, et al. Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma. Future Oncol. 2021;17(9):1055–1068.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Selective internal radiation therapies for treating hepatocellular carcinoma. Technology appraisal guidance [TA688] [Internet]. 2021. [cited 2021 May 17]. Available from: https://www.nice.org.uk/guidance/ta688.
   Google Scholar
• Latimer NR. NICE DSU Technical Support Socument 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data [Internet]. 2013. Available from: http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf.
   Google Scholar
• Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. Available from:
   PubMed Web of Science ®Google Scholar
• Coordenação de Avaliação e Monitoramento de Tecnologias, Ministério da Saúde (Brasil). Sorafenibe para carcinoma hepatocelular (CHC) avançado irressecável [Internet]. 2018 [cited 2021 May 18]. Available from: http://conitec.gov.br/images/Relatorios/2018/Relatorio_Sorafenibe_CHC-Avancado.pdf.
   Google Scholar
• Ganten TM, Stauber RE, Schott E, et al. Sorafenib in patients with hepatocellular carcinoma-results of the observational INSIGHT study. Clin Cancer Res. 2017;23(19):5720–5728.
   PubMed Web of Science ®Google Scholar
• Hospital Israelita Albert Einstein. Data on file. 2021.
   Google Scholar
• Câmara de Regulação do Mercado de Medicamentos (CMED) - Agência Nacional de Vigilância Sanitária (Anvisa). Listas de preços de medicamentos [Internet]. 2021. [cited 2021 May 19]. Available from: https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/cmed/precos.
   Google Scholar
• Campioni M, Agirrezabal I, Hajek R, et al. Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data. Eur J Health Econ. 2020;21(2):219–233. Mar
   PubMed Web of Science ®Google Scholar
• Chirivella I, Bermejo B, Insa A, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat. 2009;114(3):479–484.
   PubMed Web of Science ®Google Scholar
• Delea TE, Amdahl J, Chit A, et al. Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada. Curr Oncol. 2013;20(5):e371–e387.
   PubMed Web of Science ®Google Scholar
• Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol. 1990;8(12):1935–1937.
   PubMed Web of Science ®Google Scholar
• Ribeiro RA, Neyeloff JL, Marcolino MA, et al. Cost-Effectiveness threshold in Brazil through a league-table approach: systematic review. Value Heal. 2017;20(9):A859–A860. Available from:
   Web of Science ®Google Scholar
• Soarez PC, De Novaes HMD. Cost-effectiveness thresholds and the Brazilian Unified National Health System. Cad Saude Publica. 2017;33(4):e00040717.
   PubMed Web of Science ®Google Scholar
• The World Bank. GDP per capita (current US$) - Brazil [Internet]. 2021. [cited 2021 Jun 22]. Available from: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=BR.
   Google Scholar
• Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–124. Available from: https://pubmed.ncbi.nlm.nih.gov/25883405
   PubMed Web of Science ®Google Scholar
• Pollock RF, Colaone F, Guardiola L, et al. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. J Med Econ. 2020;23(6):593–602.
   PubMed Web of Science ®Google Scholar
• Lucà MG, Nani R, Schranz M, et al. Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib. Future Oncol. 2018;14(8):727–735.
   PubMed Web of Science ®Google Scholar
• Palmer D, Ross P, Shah T, et al. Cost effectiveness of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma patients in the UK. Ann Oncol. 2017;28:v239–v240. Available from:
   Web of Science ®Google Scholar
• Zori AG, Ismael MN, Firpi-Morell R, et al. Y90 radioembolization is a cost-effective bridging therapy for hepatocellular carcinoma: 1035. 2017;112:S574. Available from: https://journals.lww.com/ajg/Fulltext/2017/10001/Y90_Radioembolization_is_a_Cost_Effective_Bridging.1036.aspx
   Google Scholar
• Rognoni C, Ciani O, Sommariva S, et al. Real-world data for the evaluation of transarterial radioembolization versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis. Value Health. 2017;20(3):336–344. Mar
   PubMed Web of Science ®Google Scholar
• Claxton L, Walton M, Sharif-Hurst S, et al. The cost-effectiveness of selective internal radiation therapies compared with sorafenib for treating advanced unresectable hepatocellular carcinoma in the United Kingdom. Value Health. 2022;25(5):787–795.
   PubMed Web of Science ®Google Scholar
• Sirtex Medical Inc. Order-Map-Treat Program [Internet]. 2020. [cited 2021 Sep 20]. Available from: https://www.sirtex.com/media/169579/apm-us-004-12-20_order-map-treat-brochure-us_finalpdf-1.pdf.
   Google Scholar
• Pollock RF, Shergill S, Carion PL, et al. Advances in delivery of Selective Internal Radiation Therapy (SIRT): economic and logistical effects of same-stay work-up and procedure in the treatment of unresectable liver tumors in England. Adv Ther. 2023;40(1):294–309.
   PubMed Web of Science ®Google Scholar
• Sirtex Medical Inc. FLEXdose Delivery Program [Internet]. [cited 2021 Sep 10]. Available from: https://www.sirtex.com/us/clinicians/flexdose-delivery-program/.
   Google Scholar